Overview

Intermittent Versus Continuous Tarceva Study

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

This is a randomized phase II study comprising of two treatment arms in patients who are previously untreated for metastatic or recurrent colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese University of Hong Kong

Treatments:

Erlotinib Hydrochloride